Chemical Compound Review:
CI-920 sodium(6R)-6- [(1E,3R,4R,6R,7Z,9Z,11E)- 3,6...
Synonyms:
- Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia. Weinbrenner, C., Baines, C.P., Liu, G.S., Armstrong, S.C., Ganote, C.E., Walsh, A.H., Honkanen, R.E., Cohen, M.V., Downey, J.M. Circulation (1998)
- Total synthesis of fostriecin (CI-920). Boger, D.L., Ichikawa, S., Zhong, W. J. Am. Chem. Soc. (2001)
- Protein phosphatase 2A enhances activation of human immunodeficiency virus type 1 by phorbol myristate acetate. Faulkner, N.E., Lane, B.R., Bock, P.J., Markovitz, D.M. J. Virol. (2003)
- The effects of protein phosphatase inhibitors on nociceptive behavioral responses of rats following intradermal injection of capsaicin. Zhang, X., Wu, J., Fang, L., Willis, W.D. Pain (2003)
- Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. Guo, X.W., Th'ng, J.P., Swank, R.A., Anderson, H.J., Tudan, C., Bradbury, E.M., Roberge, M. EMBO J. (1995)
- Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits. Eto, M., Kitazawa, T., Brautigan, D.L. Proc. Natl. Acad. Sci. U.S.A. (2004)
- Protein phosphatase 2A inhibition induces cerebellar long-term depression and declustering of synaptic AMPA receptor. Launey, T., Endo, S., Sakai, R., Harano, J., Ito, M. Proc. Natl. Acad. Sci. U.S.A. (2004)
- Protein phosphatase inhibitors calyculin A and fostriecin protect rabbit cardiomyocytes in late ischemia. Armstrong, S.C., Gao, W., Lane, J.R., Ganote, C.E. J. Mol. Cell. Cardiol. (1998)
- Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Gorczyca, W., Gong, J., Darzynkiewicz, Z. Cancer Res. (1993)
- Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Roberge, M., Tudan, C., Hung, S.M., Harder, K.W., Jirik, F.R., Anderson, H. Cancer Res. (1994)
- Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity. Cheng, A., Balczon, R., Zuo, Z., Koons, J.S., Walsh, A.H., Honkanen, R.E. Cancer Res. (1998)
- Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells. Hotz, M.A., Del Bino, G., Lassota, P., Traganos, F., Darzynkiewicz, Z. Cancer Res. (1992)
- Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation. Hotz, M.A., Traganos, F., Darzynkiewicz, Z. Exp. Cell Res. (1992)
- The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization. Ho, D.T., Roberge, M. Carcinogenesis (1996)
- Two modes of exocytosis from synaptosomes are differentially regulated by protein phosphatase types 2A and 2B. Baldwin, M.L., Rostas, J.A., Sim, A.T. J. Neurochem. (2003)
- Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Du, D.L., Volpe, D.A., Grieshaber, C.K., Murphy, M.J. Investigational new drugs. (1991)
- Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. Pandey, A.V., Mellon, S.H., Miller, W.L. J. Biol. Chem. (2003)
- p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. Zhu, C.B., Carneiro, A.M., Dostmann, W.R., Hewlett, W.A., Blakely, R.D. J. Biol. Chem. (2005)
- Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells. Gedik, C.M., Collins, A.R. Nucleic Acids Res. (1990)
- Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Honkanen, R.E., Golden, T. Current medicinal chemistry. (2002)
- Positive regulation of IkappaB kinase signaling by protein serine/threonine phosphatase 2A. Kray, A.E., Carter, R.S., Pennington, K.N., Gomez, R.J., Sanders, L.E., Llanes, J.M., Khan, W.N., Ballard, D.W., Wadzinski, B.E. J. Biol. Chem. (2005)
- Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes. Liu, Q., Hofmann, P.A. Am. J. Physiol. Heart Circ. Physiol. (2004)
- CRHSP-24 phosphorylation is regulated by multiple signaling pathways in pancreatic acinar cells. Schäfer, C., Steffen, H., Krzykowski, K.J., Göke, B., Groblewski, G.E. Am. J. Physiol. Gastrointest. Liver Physiol. (2003)
- Okadaic acid overcomes the blocked cell cycle caused by depleting Cdc2-related kinases in Trypanosoma brucei. Li, Z., Tu, X., Wang, C.C. Exp. Cell Res. (2006)
- Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells. Anderson, H., Roberge, M. Cell Growth Differ. (1996)
- Fostriecin: chemistry and biology. Lewy, D.S., Gauss, C.M., Soenen, D.R., Boger, D.L. Current medicinal chemistry. (2002)
- Inhibition of type II topoisomerase by fostriecin. Boritzki, T.J., Wolfard, T.S., Besserer, J.A., Jackson, R.C., Fry, D.W. Biochem. Pharmacol. (1988)
- Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. Pillon, L., Moore, M.J., Thiessen, J.J. Therapeutic drug monitoring. (1994)